M.S.Q. Ventures is pleased to announce that its client, BioLineRx, has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. and an associated investor for the development of motixafortide across all indications in Asia. The license agreement provides for a $15M upfront payment and an equity investment of $14.6M, up to $50M in potential development and regulatory milestones, up to $200M in potential commercial milestones and tiered double-digit royalties on sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLRX:
- BioLineRx closes exclusive license agreement with Guangzhou Gloria Biosciences
- Largest borrow rate increases among liquid names
- BioLineRx’s motixafortide shows ‘encouraging’ efficacy in pancreatic cancer
- BioLineRx price target raised to $21 from $19 at H.C. Wainwright
- BioLineRx announces FDA approval of APHEXDA/filgrastim combination
